MedPath
HSA Approval

LOTYRO 150 ERLOTINIB FILM COATED TABLETS 150MG

SIN17080P

LOTYRO 150 ERLOTINIB FILM COATED TABLETS 150MG

LOTYRO 150 ERLOTINIB FILM COATED TABLETS 150MG

September 11, 2024

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

L01EB02

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

MSN Laboratories Private Limited

Active Ingredients

Erlotinib hydrochloride eqv Erlotininb

150.000mg

Documents

Package Inserts

Lotyro FC Tablet package insert.pdf

Approved: September 11, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LOTYRO 150 ERLOTINIB FILM COATED TABLETS 150MG - HSA Approval | MedPath